Public disclosure of inside information according to article 17 MAR
Medigene submits CTA for its first TCR clinical trial and announces milestone payment
Planegg (pta028/10.07.2017/15:35) -
Medigene AG (MDG1, Frankfurt, Prime Standard, TecDAX) has filed a clinical trial authorization application (CTA) to begin the Company's first clinical trial with proprietary T-cell receptor- (TCR) modified T cells as an immunotherapy to treat a range of blood cancer indications. The CTA was submitted to the German authority Paul-Ehrlich-Institute (PEI) today. As previously announced, Medigene expects to start this trial by year end 2017.
The CTA submission triggers a final milestone payment of EUR 2.0 million from Medigene AG to the former contributing shareholders of Medigene Immunotherapies GmbH (formerly: Trianta Immunotherapies GmbH) within the next five months. Medigene intends to settle this payment through the issuance of new shares from authorized capital. The milestone payment was an agreed part of the purchase price for the acquisition of Trianta in January 2014. With this third and final milestone payment, the total purchase price of approximately EUR 10 million will have been entirely settled.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01
Lochhamer Straße 11
||Julia Hofmann, Head of Public and Investor Relations
||+49 89 200033-3301
||regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Hannover, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate